Check back soon for updates on recent transactions and upcoming company growth strategies. Highlights of our company profile include:
As of March 22, 2013, affiliates of Aurora Capital were elected to a majority of Board of Directors and Executive Team positions at Cortex Pharmaceuticals, Inc. (CORX). For more information, view recent filings and news.
Form 3 Filings: 4/1/2013 Initial Statement of Beneficial Ownership of Securities
Form_8K_Filing: 3/22/2013 Cortex Pharmaceuticals, Inc. - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Form_8K_Filing: 3/22/2013 Termination of licensing agreement between Univeristy of Illinois and Pier Pharmaceuticals, Inc., a wholly-owned subsidiary of Cortex Pharmaceuticals, Inc. (CORX)
Schedule_13D_Filing: 3/21/2013 Aurora affiliates acquire beneficial ownership of publicly traded securities in Cortex Pharmaceuticals, Inc. (CORX)
In December 2009 Aurora announced that South Florida-and-San Francisco-based LifeTech_Capital joined the firm as an independent division of Aurora's investment banking group. The new division is led by Robert D. Keyser, CEO of LifeTech Capital and Senior Managing Director of Investment Banking, and Stephen M. Dunn, President of LifeTech Capital and Senior Managing Director of Research. The LifeTech Capital division provides PIPE, overnight, and registered direct finance opportunities to the firm's corporate finance clients, and provides research for public distribution. LifeTech Capital also participates in Aurora's earlier-stage transactions. Mr. Keyser and Mr. Dunn have developed widely-respected reputations while at their previous leadership positions at Dawson James Securities and Jesup & Lamont, respectively. The LifeTech Capital team, is currently comprised of four individuals, with over 50 years of combined experience in the sector.
During the past three years, Aurora has assisted in the formation and initial financing of Xintria Pharmaceutical Corporation. Xintria was formed in May 2006 and licensed intellectual property rights from the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences for therapeutic uses of a compound (along with analogs, derivatives and reformulations of that compound) that is on the market in China for an indication other than those of interest to Xintria. Aurora was instrumental in the license negotiations, assessment and protection of the intellectual property, hiring the executive management team, formation of the Board of Directors, due diligence, and writing of the business plan. Aurora affiliates are executive officers of Xintria and members of the Board of Directors.
Over the past 18 years Aurora has successfully provided expertise and value added services to the life sciences markets.
For the past year management has dedicated efforts and resources to the strategic advancement of the firm and its capabilities.
Providing quality and focused full-service investment banking, strategic consulting and investment and brokerage services.
Please visit this page in the future for news from Aurora Capital.